PROM1 and neoplasm: The CD44v6-positive tumor cell area was slightly (but not significantly) lower for VS-6063−treated tumors relative to the vehicle group (Fig 6A and 6C), suggesting that our novel anti-CD133 antibody may allow for more sensitive detection of CSC modulation in the SUM149PT model.